Medulloblastoma and the DNA Damage Response

Area of Science:

• Pediatric Oncology
• Cancer Genomics
• Molecular Biology

Background:

• Medulloblastoma (MB) is the most common malignant pediatric brain tumor.
• Current treatments include surgery, radiation, and chemotherapy, often guided by histology rather than molecular profile.
• Four distinct molecular subgroups (WNT, SHH, Group 3, Group 4) have been identified, yet treatment stratification remains limited.

Purpose of the Study:

• To explore the potential of targeting DNA damage response (DDR) pathways in medulloblastoma.
• To discuss the molecular basis of genomic instability in MB.
• To identify novel therapeutic strategies for MB irrespective of molecular subgroup.

Main Methods:

• Review of molecular underpinnings of genomic instability in medulloblastoma.
• Analysis of DNA damage response (DDR) pathways relevant to cancer therapy.
• Exploration of DDR inhibitors as potential therapeutic agents for MB.

Main Results:

• Genomic instability is a key feature of medulloblastoma.
• DNA damage response (DDR) proteins are critical for cancer cell survival.
• DDR inhibitors show promise as monotherapy or in combination for various cancers.

Conclusions:

• Targeting DNA damage repair mechanisms presents a viable therapeutic strategy for medulloblastoma.
• Inhibitors of DDR proteins could offer a broad-impact approach across all MB molecular subgroups.
• Further research into DDR inhibition is warranted for developing novel MB treatments.